ADMA Biologics Inc (NASDAQ:ADMA) – Equities researchers at Oppenheimer issued their Q1 2020 earnings per share (EPS) estimates for ADMA Biologics in a research report issued on Thursday, November 7th. Oppenheimer analyst L. Gershell anticipates that the biotechnology company will post earnings per share of ($0.10) for the quarter. Oppenheimer also issued estimates for ADMA Biologics’ Q2 2020 earnings at ($0.10) EPS, Q3 2020 earnings at ($0.09) EPS, Q4 2020 earnings at ($0.08) EPS and FY2021 earnings at $0.08 EPS.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. The firm had revenue of $7.22 million during the quarter, compared to the consensus estimate of $5.71 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.
Other equities analysts also recently issued reports about the company. Dawson James downgraded ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price target for the company. in a report on Monday, August 12th. Maxim Group set a $12.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Monday, October 21st. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. ADMA Biologics has a consensus rating of “Buy” and a consensus price target of $10.20.
ADMA traded down $0.21 on Friday, reaching $4.31. The company’s stock had a trading volume of 940,100 shares, compared to its average volume of 884,660. The stock has a 50 day moving average of $4.59 and a two-hundred day moving average of $4.26. The company has a quick ratio of 7.93, a current ratio of 10.26 and a debt-to-equity ratio of 1.79. The company has a market capitalization of $304.89 million, a price-to-earnings ratio of -2.97 and a beta of 2.70. ADMA Biologics has a fifty-two week low of $2.08 and a fifty-two week high of $6.31.
Several hedge funds have recently bought and sold shares of ADMA. Private Advisors LLC acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $41,000. Parametric Portfolio Associates LLC acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $49,000. Tower Research Capital LLC TRC boosted its holdings in shares of ADMA Biologics by 13,268.0% in the second quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 13,268 shares during the period. Citadel Advisors LLC boosted its holdings in shares of ADMA Biologics by 96.3% in the second quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 10,887 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of ADMA Biologics by 55.9% in the third quarter. Rhumbline Advisers now owns 45,841 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 16,443 shares during the period. 59.10% of the stock is owned by institutional investors and hedge funds.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Story: Outstanding Shares
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.